Compare Illumina, Inc. (ILMN) vs ProShares Ultra QQQ ETF (QLD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Illumina, Inc. vs ProShares Ultra QQQ ETF — how do they compare? Illumina, Inc. trades at $268.5 (market cap $39.95B), while ProShares Ultra QQQ ETF trades at $97.85 (market cap $15.38B). The key difference: Illumina, Inc. is far larger — about 2.6× ProShares Ultra QQQ ETF's market cap, and ProShares Ultra QQQ ETF is more actively traded (4,844,085 versus 3,169,503). Which is the better fit depends on your goals — on Pluang, investors hold Illumina, Inc. for 83 Days and ProShares Ultra QQQ ETF for 37 Days on average.
| ILMN | QLD | |
|---|---|---|
Market Cap | $39.95B | $15.38B |
Volume | 3,169,503 | 4,844,085 |
Sector | Health | Leveraged / Inverse |
52-Week High | $293.69 | $100.77 |
52-Week Low | $91.00 | $57.16 |
Typical Hold Time | 83 Days | 37 Days |
Enterprise Value | $41.31B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Illumina (ILMN) trades at $267.76, down 2.11% today but remains near recent highs after a strong 94.9% YTD rally. The stock shows bullish technical momentum with recent earnings beats and improved profitability, with net income turning positive to $850 million in 2025 after previous losses. S&P 500 inclusion in September 2026 and growing AI integration in genomics provide positive catalysts, though valuation metrics remain elevated with a P/E of 49.36.
Outlook remains positive with analyst consensus favoring Buy ratings (54%) and a $241 price target, though current price exceeds consensus. Key opportunities include sequencing growth and AI adoption, while risks include China headwinds, margin pressure, and high valuation multiples requiring sustained execution to justify premium pricing.
QLD trades at $100.23, down 0.54% on the day, with technical indicators showing a bullish moving average signal but overbought RSI conditions. The ETF maintains support at $99 and resistance at $101, with institutional buying activity noted in recent filings. Recent news highlights QLD's resilience compared to more leveraged alternatives during market downturns.
The outlook remains cautiously optimistic given strong technical momentum, though overbought conditions suggest potential near-term consolidation. Key risks include Federal Reserve policy impacts and Nasdaq volatility, while institutional accumulation supports medium-term bullish sentiment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Illumina, Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →About ProShares Ultra QQQ ETF
QLD is a leveraged ETF that seeks daily investment results corresponding to 200% of the daily performance of the NASDAQ-100 Index. It achieves 2x leverage by investing in financial instruments such as swaps and is designed as a tactical trading tool for investors with a bullish (long) view on the NASDAQ-100. Due to the effects of compounding and leverage, the ETF is intended to be held for a single day and is not suitable for long-term investment.
Read more on QLD →
